BeStock  
Stocks › Biotechnology › JANX

Janux Therapeutics JANX

US equityMarket cap rank #3178Biotechnology
$17.92 +$1.13 (+6.73%)
Pre-market · Oct 8, 8:20 am ET · After hours $18.50 +3.24%
Open$16.52
Prev close$16.79
Day range$16.42 – $18.37
Volume1.21M
Market cap$1.10B
P/E (TTM)–
Dividend yield–

Price chart

Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view). Triangles mark past earnings reports, colored by that day’s move; ticks mark ex-dividend dates — hover either for the date. Volume is the shaded bars under the price; switch on RSI or MACD above for a full-history oscillator panel, or Bollinger Bands for the same 20-day/2-standard-deviation channel used in the Technical signals table.

Technical signals

Trend readStrong uptrend

6 bullish · 0 bearish of 7 signals

IndicatorValueSignalReading
Price vs 20-day average+6.0%BullishTrading above the 20-day average of $16.91
Price vs 50-day average+4.3%BullishTrading above the 50-day average of $17.19
Price vs 200-day average+19.2%BullishTrading above the 200-day average of $15.04
50-day vs 200-day50d above 200dBullishThe 50-day average is above the 200-day average
RSI (14)56.5BullishMomentum leans positive
MACD (12,26,9)-0.11BullishMACD line is above its signal line
Bollinger band position106%NeutralAbove the upper band, an extended move

Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.

Levels & volatility

Moving averages

AverageLevelPrice vs. it
20-day SMA$16.91+6.0%
50-day SMA$17.19+4.3%
200-day SMA$15.04+19.2%

Recent price levels

LevelPrice
20-day high$19.33
20-day low$15.75
60-day high$20.31
60-day low$14.57
Upper Bollinger band$17.81
Lower Bollinger band$16.00

The 50-day average is currently 14.3% above the 200-day average — consistent with a “golden cross” (bullish) configuration.

30-day volatility52.8%
Average true range4.45% of price
Max drawdown (1y)-64.9%
Volume (10d vs 90d)0.82x

Discussion

No comments yet — be the first to weigh in on JANX.

Leave a comment

Scroll to Top